Ken Fisher & Jim Simons: Two Billionaires Bulking Up On Drugs

Page 1 of 2

FISHER ASSET MANAGEMENTBillionaires Ken Fisher and Jim Simons are two of the top names in the money management business. Fisher runs Fisher Asset Management and is also a long-time columnist for Forbes. Fisher founded Fisher Asset Management in 1979 and has been writing for Forbes for over 25 years. Here’s Ken Fisher’s full equity portfolio.

Simons founded Renaissance Technologies (RenTech) in 1982 and the firm continues to manage various hedge funds across the world. Simons’ Medallion Fund is one of the best in the industry, making Simons a very rich man while using high frequency trading to exploit inefficiencies in the stock market. Simons stepped down as CEO of RenTech in 2010 and the fund’s investors are now mainly current and past employees (check out Jim Simons’ latest picks).

In reviewing the duo’s latest 13F filings with the SEC – which reveal most of the publicly traded securities that each manager owns – we found that Fisher and Simons both have big bets in the pharma industry. Fisher and Simons each have two pharma stocks in their top five holdings, and have almost $3 billion invested cumulatively across five big-name pharma companies.

Our first pharma company is Fisher’s number one stock holding in his 13F, Pfizer Inc. (NYSE:PFE). Fisher increased his stake in Pfizer by 45% last quarter after the pharma stock traded relatively flat in 2Q. Pfizer completed the sale of its nutrition business to Nestle for $11 billion, which puts it on its path for realignment. Spurring Pfizer on will be its plan to IPO some 20% of its animal health business, with proceeds used to drive further dividend increases and its $10 billion share repurchase program that was recently announced.

Johnson & Johnson (NYSE:JNJ) is another one of Fisher’s big time bets, being the second largest stock holding in his 3Q 13F. Revenues are expected to be up 8% in 2013 thanks in part to a full year of Synthes’ integrated sales. The Synthes acquisition will help Johnson & Johnson expand its product offering to more orthopedic products, and is expected to add $4 billion in sales in 2013. Fellow billionaire investor George Soros also has Johnson & Johnson as one of his latest bets, increasing his stake by over 1500% during the third quarter (check out George Soros’ new picks).

GlaxoSmithKline PLC (NYSE:GSK) is another one of Fisher’s pharma bets and is the 23rd largest holding in his 13F portfolio. Fisher increased his stake by 130% last quarter. Revenues for Glaxo are expected to be flat for 2012 as the pharma company sees erosion in older drug lines. Volume gains in new pharmaceuticals, such as Lovaza, should help counter this erosion in the interim, and is expected to drive sales growth in the mid-single digits for 2013. Glaxo will likely see the most pressure of our five pharma stocks given its above-average exposure to Europe.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!